PolyPeptide Group AG
Stock Forecast, Prediction & Price Target

	Passed			Analyst forecast
Metric	12/31/2021	12/31/2022	12/31/2023	12/31/2025	12/31/2026
Revenue % change YoY	CHF282.12M N/A	CHF280.97M -0.40%	CHF320.37M 14.02%	Avg: CHF411.19M Low: CHF392.60M High: CHF435.84M avg. 28.34%	Avg: CHF486.97M Low: CHF471.81M High: CHF505.64M avg. 18.42%
Net Income % change YoY	CHF47.25M N/A	CHF7.76M -83.56%	CHF-51.44M -762.28%	Avg: CHF14.89M Low: CHF12.05M High: CHF23.16M avg. 128.95%	Avg: CHF38.43M Low: CHF35.45M High: CHF45.75M avg. 157.99%
EBITDA % change YoY	CHF83.45M N/A	CHF33.05M -60.39%	CHF-22.15M -167.01%	Avg: CHF69.79M Low: CHF66.63M High: CHF73.97M avg. 415.08%	Avg: CHF82.65M Low: CHF80.08M High: CHF85.82M avg. 18.42%
EPS % change YoY	$1.47 N/A	$0.24 -83.67%	-$1.56 -750.00%	Avg: $0.55 Low: $0.37 High: $0.7 avg. 135.38%	Avg: $1.24 Low: $1.08 High: $1.39 avg. 124.46%
Operating Expenses % change YoY	CHF37.03M N/A	CHF42.34M 14.32%	CHF41.11M -2.90%	Avg: CHF40.63M Low: CHF38.79M High: CHF43.07M avg. -1.15%	Avg: CHF48.12M Low: CHF46.62M High: CHF49.96M avg. 18.42%

FAQ

Wall Street analysts estimate the annual average earnings growth rate of 143.47% in 2025-2026.

We have gathered data from 4 analysts. Their low estimate is 12.05M, average is 14.89M and high is 23.16M.

Wall Street analysts forecast annual average revenue growth of 23.38% in 2025-2026.

We have gathered data from 5 analysts. Their low revenue estimate is CHF392.60M, average is CHF411.19M and high is CHF435.84M.

Wall Street analysts forecast annual average earnings growth of 129.92% in 2025-2026.

We have gathered data from 4 analysts. Their low earnings per share estimate is $0.37, average is $0.55 and high is CHF0.70.